29 results on '"Giralt, Sergio"'
Search Results
2. Impact of Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
- Author
-
Shouval, Roni, Alarcon Tomas, Ana, Fein, Joshua A, Flynn, Jessica R, Markovits, Ettai, Mayer, Shimrit, Olaide Afuye, Aishat, Alperovich, Anna, Anagnostou, Theodora, Besser, Michal J, Batlevi, Connie Lee, Dahi, Parastoo B, Devlin, Sean M, Fingrut, Warren B, Giralt, Sergio A, Lin, Richard J, Markel, Gal, Salles, Gilles, Sauter, Craig S, and Scordo, Michael
- Published
- 2022
- Full Text
- View/download PDF
3. Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome.
- Author
-
Dillon, Laura W., Gui, Gege, Logan, Brent R., Fei, Mingwei, Ghannam, Jack, Li, Yuesheng, Licon, Abel, Alyea, Edwin P., Bashey, Asad, Devine, Steven M., Fernandez, Hugo F., Giralt, Sergio, Hamadani, Mehdi, Howard, Alan, Maziarz, Richard T., Porter, David L., Warlick, Erica D., Pasquini, Marcelo C., Scott, Bart L., and Horwitz, Mitchell E.
- Subjects
HEMATOPOIETIC stem cell transplantation ,MYELODYSPLASTIC syndromes ,DNA sequencing ,OVERALL survival ,GENOMICS ,PRELEUKEMIA - Abstract
PURPOSE: Patients with myelodysplastic syndrome (MDS) are at risk of relapse after allogeneic hematopoietic cell transplantation. The utility of ultra-deep genomic testing to predict and the impact of conditioning intensity to prevent MDS relapse are unknown. METHODS: Targeted error-corrected DNA sequencing was performed on preconditioning blood samples from patients with MDS (n = 48) from the Blood and Marrow Transplant Clinical Trials Network 0901 phase III randomized clinical trial, which compared outcomes by allogeneic hematopoietic cell transplantation conditioning intensity in adult patients with < 5% marrow myeloblasts and no leukemic myeloblasts in blood on morphological analysis at the time of pretransplant assessment. Clinical end points (53-month median follow-up) included transplant-related mortality (TRM), relapse, relapse-free survival (RFS), and overall survival (OS). Of the 48 patients examined, 14 experienced TRM, 23 are relapse-free, and 11 relapsed, of which 7 died. RESULTS: Using a previously described set of 10 gene regions, 42% of patients (n = 20) had mutations detectable before random assignment to reduced intensity conditioning (RIC) or myeloablative conditioning (MAC). Testing positive was associated with increased rates of relapse (3-year relapse, 40% v 11%; P =.022) and decreased OS (3-year OS, 55% v 79%, P =.045). In those testing positive, relapse rates were higher (3-year relapse, 75% v 17%; P =.003) and RFS was lower (3-year RFS, 13% v 49%; P =.003) in RIC versus MAC arms. Testing additional genes, including those associated with MDS, did not improve prognostication. CONCLUSION: This study provides evidence that targeted DNA sequencing in patients with MDS before transplant can identify those with highest post-transplant relapse rates. In those testing positive, random assignment to MAC lowered but did not eliminate relapse risk. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
- Author
-
Hourigan, Christopher S., Dillon, Laura W., Gui, Gege, Logan, Brent R., Fei, Mingwei, Ghannam, Jack, Li, Yuesheng, Licon, Abel, Alyea, Edwin P., Bashey, Asad, Deeg, H. Joachim, Devine, Steven M., Fernandez, Hugo F., Giralt, Sergio, Hamadani, Mehdi, Howard, Alan, Maziarz, Richard T., Porter, David L., Scott, Bart L., and Warlick, Erica D.
- Published
- 2020
- Full Text
- View/download PDF
5. Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
- Author
-
Firestone, Ross, Shekarkhand, Tala, Patel, Dhwani, Tan, Carlyn Rose Co, Hultcrantz, Malin, Lesokhin, Alexander M., Mailankody, Sham, Hassoun, Hani, Shah, Urvi A, Korde, Neha, Maclachlan, Kylee, Landau, Heather Jolie, Scordo, Michael, Chung, David J., Shah, Gunjan L., Lahoud, Oscar Boutros, Giralt, Sergio, and Usmani, Saad Zafar
- Published
- 2023
- Full Text
- View/download PDF
6. Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase...
- Author
-
Delforge, Michel, Patel, Krina K., Eliason, Laurie, Dhanda, Devender, Shi, Ling, Guo, Shien, Marshall, Thomas, Arnulf, Bertrand, Cavo, Michele, Nooka, Ajay K., Manier, Salomon, Callander, Natalie Scott, Giralt, Sergio, Einsele, Hermann, Ailawadhi, Sikander, Popa McKiver, Mihaela, Cook, Mark, and Rodríguez-Otero, Paula
- Published
- 2023
- Full Text
- View/download PDF
7. Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.
- Author
-
Shah, Gunjan L., Hanley, Danielle, Datta, Ambika, Kamrowski, Alyssa, Chung, David J., Gupta, Gaurav K., Hassoun, Hani, Hoover, Elizabeth, Hultcrantz, Malin, Korde, Neha, Lahoud, Oscar Boutros, Landau, Heather Jolie, Lesokhin, Alexander M., Scordo, Michael, Shah, Urvi A, Tan, Carlyn Rose Co, Usmani, Saad Zafar, Mohanlal, Ramon W., and Giralt, Sergio
- Published
- 2023
- Full Text
- View/download PDF
8. The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation.
- Author
-
Yu, Kenneth H., Weekes, Colin D., Chen, Yi-Bin Albert, Glazier, Jeffrey Aaron, Glazier, Arnold, Dahi, Parastoo, Giralt, Sergio, and O'Reilly, Eileen Mary
- Published
- 2023
- Full Text
- View/download PDF
9. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
- Author
-
Scott, Bart L., Pasquini, Marcelo C., Logan, Brent R., Juan Wu, Devine, Steven M., Porter, David L., Maziarz, Richard T., Warlick, Erica D., Fernandez, Hugof., Alyea, Edwin P, Hamadani, Mehdi, Bashey, Asad, Giralt, Sergio, Geller, Nancy L., Leifer, Eric, Le-Rademacher, Jennifer, Mendizabal, Adam M., Horowitz, Mary M., Deeg, H. Joachim, and Horwitz, Mitchell E.
- Published
- 2017
- Full Text
- View/download PDF
10. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in...
- Author
-
Devine, Steven M., Owzar, Kouros, Blum, William, Mulkey, Flora, Stone, Richard M., Hsu, Jack W., Champlin, Richard E., Yi-Bin Chen, Vij, Ravi, Slack, James, Soiffer, Robert J., Larson, Richard A., Shea, Thomas C., Hars, Vera, Sibley, Alexander B., Giralt, Sergio, Carter, Shelly, Horowitz, Mary M., Linker, Charles, and Alyea, Edwin P.
- Published
- 2015
- Full Text
- View/download PDF
11. Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Where Are We Going With This?
- Author
-
Giralt, Sergio
- Subjects
- *
GRAFT versus host disease prevention , *HEMATOPOIETIC stem cell transplantation , *MYELODYSPLASTIC syndromes - Abstract
In the article, the author discusses issues in the use of allogeneic hematopoietic cell transplantation (HCT) as a curative therapy for myelodysplastic syndromes (MDS) in the U.S. as of September 2016. Also cited are the decision by the U.S. Centers for Medicare & Medicaid Services to allow Medicare coverage to allogeneic hematopoietic stem cell transplantation (HSCT) for MDS, and the importance of clinical trials in MDS.
- Published
- 2016
- Full Text
- View/download PDF
12. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
- Author
-
Hourigan, Christopher S, Dillon, Laura W, Gui, Gege, Logan, Brent R, Fei, Mingwei, Ghannam, Jack, Li, Yuesheng, Licon, Abel, Alyea, Edwin P, Bashey, Asad, Deeg, H Joachim, Devine, Steven M, Fernandez, Hugo F, Giralt, Sergio, Hamadani, Mehdi, Howard, Alan, Maziarz, Richard T, Porter, David L, Scott, Bart L, and Warlick, Erica D
- Published
- 2019
- Full Text
- View/download PDF
13. Graft-Versus-Host Disease: Have We Solved the Problem?
- Author
-
Giralt, Sergio
- Published
- 2012
- Full Text
- View/download PDF
14. Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.
- Author
-
Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Krishnan A, Landau H, Somlo G, Shah N, Stadtmauer E, Vogl DT, Vesole DH, McCarthy PL, and Hahn T
- Abstract
Purpose: Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by next-generation multiparameter flow cytometry (MFC). Patients were enrolled on a three-arm randomized control trial (Blood and Marrow Transplants Clinical Trials Network 0702 Stem Cell Transplant for Myeloma in Combination of Novel Agents [STaMINA]; ClinicalTrials.gov identifier: NCT01109004)., Methods: Four hundred and thirty-five patients consented to the MRD panel, which included 10 monoclonal antibodies measured via six-color MFC. MRD was measured at baseline/preautologous hematopoietic cell transplant (BL/preAutoHCT), premaintenance (PM), and 1 year (Y1) after AutoHCT with a sensitivity of 10
-5 to 10-6 . The primary objective was to assess MRD-negative (MRDneg ) at 1 year after AutoHCT and progression-free survival and overall survival (PFS/OS)., Results: Similar to the STaMINA results, at a median follow-up of 70 months, there was no significant difference in PFS/OS by treatment arm in the PRIMeR patients. MRDneg at all three time points was associated with significantly improved PFS, and MRDneg at Y1 had significantly longer OS. Multivariate analysis of PFS, adjusting for disease risk and treatment arm, demonstrated hazard ratios (HRs) in MRD-positive patients compared with MRDneg patients at BL, PM, and Y1 of 1.55 ( P = .0074), 1.83 ( P = .0007), and 3.61 ( P < .0001), respectively. Corresponding HRs for OS were 1.19 ( P = .48), 0.88 ( P = .68), and 3.36 ( P < .001). Patients with sustained MRDneg or who converted to MRDneg by Y1 had similar PFS/OS., Conclusion: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.- Published
- 2024
- Full Text
- View/download PDF
15. Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
- Author
-
Shouval R, Alarcon Tomas A, Fein JA, Flynn JR, Markovits E, Mayer S, Olaide Afuye A, Alperovich A, Anagnostou T, Besser MJ, Batlevi CL, Dahi PB, Devlin SM, Fingrut WB, Giralt SA, Lin RJ, Markel G, Salles G, Sauter CS, Scordo M, Shah GL, Shah N, Scherz-Shouval R, van den Brink M, Perales MA, and Palomba ML
- Subjects
- Aged, Biological Products therapeutic use, DNA Copy Number Variations, Female, Gene Dosage, Gene Expression Profiling, High-Throughput Nucleotide Sequencing, Humans, Lymphoma, B-Cell genetics, Lymphoma, B-Cell immunology, Lymphoma, B-Cell mortality, Male, Middle Aged, Mutation, Predictive Value of Tests, Receptors, Antigen, T-Cell therapeutic use, Receptors, Chimeric Antigen genetics, Retrospective Studies, Risk Assessment, Risk Factors, T-Lymphocytes immunology, Time Factors, Treatment Outcome, Antigens, CD19 immunology, Biomarkers, Tumor genetics, Immunotherapy, Adoptive adverse effects, Immunotherapy, Adoptive mortality, Lymphoma, B-Cell therapy, Receptors, Chimeric Antigen immunology, T-Lymphocytes transplantation, Tumor Suppressor Protein p53 genetics
- Abstract
Purpose: Tumor-intrinsic features may render large B-cell lymphoma (LBCL) insensitive to CD19-directed chimeric antigen receptor T cells (CAR-T). We hypothesized that TP53 genomic alterations are detrimental to response outcomes in LBCL treated with CD19-CAR-T., Materials and Methods: Patients with LBCL treated with CD19-CAR-T were included. Targeted next-generation sequencing was performed on pre-CAR-T tumor samples in a subset of patients. Response and survival rates by histologic, cytogenetic, and molecular features were assessed. Within a cohort of newly diagnosed LBCL with genomic and transcriptomic profiling, we studied interactions between cellular pathways and TP53 status., Results: We included 153 adults with relapsed or refractory LBCL treated with CD19-CAR-T (axicabtagene ciloleucel [50%], tisagenlecleucel [32%], and lisocabtagene maraleucel [18%]). Outcomes echoed pivotal trials: complete response (CR) rate 54%, median overall survival (OS) 21.1 months (95% CI, 14.8 to not reached), and progression-free survival 6 months (3.4 to 9.7). Histologic and cytogenetic LBCL features were not predictive of CR. In a subset of 82 patients with next-generation sequencing profiling, CR and OS rates were comparable with the unsequenced cohort. TP53 alterations (mutations and/or copy number alterations) were common (37%) and associated with inferior CR and OS rates in univariable and multivariable regression models; the 1-year OS in TP53 -altered LBCL was 44% (95% CI, 29 to 67) versus 76% (65 to 89) in wild-type ( P = .012). Transcriptomic profiling from a separate cohort of patients with newly diagnosed lymphoma (n = 562) demonstrated that TP53 alterations are associated with dysregulation of pathways related to CAR-T-cell cytotoxicity, including interferon and death receptor signaling pathway and reduced CD8 T-cell tumor infiltration., Conclusion: TP53 is a potent tumor-intrinsic biomarker that can inform risk stratification and clinical trial design in patients with LBCL treated with CD19-CAR-T. The role of TP53 should be further validated in independent cohorts., Competing Interests: Roni ShouvalConsulting or Advisory Role: Medexus, MyBiotics Michal J. BesserEmployment: Envizion Medical (I)Leadership: Envizion Medical (I)Stock and Other Ownership Interests: Envizion Medical (I)Consulting or Advisory Role: Biological Industries (a Sartorius Company), Gilboa TherapeuticsPatents, Royalties, Other Intellectual Property: Patents at Envizion Medical (I), Royalties at Biological Industries (Inst)Travel, Accommodations, Expenses: Lonza Connie Lee BatleviStock and Other Ownership Interests: Moderna Therapeutics, Novavax, Pfizer, Bristol Myers Squibb, Regeneron, ViatrisHonoraria: DAVA OncologyConsulting or Advisory Role: LifeSci Capital, GLG, Juno Therapeutics, Celgene, Seattle Genetics, Kite, a Gilead company, TG Therapeutics, Karyopharm TherapeuticsResearch Funding: Janssen Biotech (Inst), Novartis (Inst), Epizyme (Inst), Xynomic Pharma (Inst), Bayer (Inst), Roche (Inst), Autolus (Inst)Open Payments Link: https://openpaymentsdata.cms.gov/physician/2778694 Parastoo B. DahiConsulting or Advisory Role: Kite, a Gilead company Sean M. DevlinThis author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Sergio A. GiraltHonoraria: Celgene, Takeda, Amgen, Jazz Pharmaceuticals, Sanofi,Consulting or Advisory Role: Celgene, Takeda, Sanofi, Jazz Pharmaceuticals, Amgen, Janssen, Actinuum, Bristol Myers Squibb, Johnson & Johnson, PfizerResearch Funding: Celgene (Inst), Miltenyi Biotec, Johnson & Johnson, Amgen, Actinuum, SanofiTravel, Accommodations, Expenses: Celgene, Sanofi, Amgen, Jazz Pharmaceuticals Richard J. LinEmployment: Pfizer (I)Consulting or Advisory Role: Kite/Gilead Gal MarkelEmployment: 4C Biomed, Ella TherapeuticsLeadership: 4C Biomed, Ella TherapeuticsStock and Other Ownership Interests: Purple Biotech, Biond Biologics, Nucleai, Staburo GmbH, Ella Therapeutics, 4C BiomedHonoraria: BMS, MSD, Novartis, Medison, RocheConsulting or Advisory Role: MSD, NovartisSpeakers' Bureau: MSD, BMSResearch Funding: Novartis (Inst), Immunicom (Inst)Patents, Royalties, Other Intellectual Property: Patent on anti-CEACAM1 blocking antibodiesTravel, Accommodations, Expenses: BMS, Novartis, MSD Gilles SallesHonoraria: Roche/Genentech, Janssen, Celgene, Gilead Sciences, Novartis, AbbVie, MorphoSysConsulting or Advisory Role: Roche/Genentech, Gilead Sciences, Janssen, Celgene, Novartis, MorphoSys, Epizyme, Alimera Sciences, Genmab, Debiopharm Group, Velosbio, BMS, BeiGene, Incyte, Miltenyi Biotec, Ipsen Craig S. SauterConsulting or Advisory Role: Spectrum Pharmaceuticals, Juno Therapeutics, Sanofi, Gilead Sciences, Novartis¸ Precision BioSciences, Gamida Cell, Karyopharm Therapeutics, GlaxoSmithKline, GenmabResearch Funding: Juno Therapeutics (Inst), Sanofi (Inst), Precision BioSciences (Inst), BMS (Inst), Actinium Pharmaceuticals (Inst)Travel, Accommodations, Expenses: Juno Therapeutics, Sanofi, Gilead Sciences, Novartis Michael ScordoHonoraria: i3 CMEConsulting or Advisory Role: McKinsey & Company, Angiocrine Bioscience, OmerosResearch Funding: Angiocrine Bioscience, Omeros (Inst)Travel, Accommodations, Expenses: Kite/Gilead Gunjan L. ShahResearch Funding: Amgen (Inst), Janssen (Inst) Marcel van den BrinkHonoraria: Seres Therapeutics, Merck, Magenta Therapeutics, WindMIL, Rheos Medicines, Frazier Healthcare Partners, Nektar, Notch Therapeutics, Forty Seven, Priothera, Ceramedix, LyGenesis, Pluto Therapeutics, GlaxoSmithKline, Da Volterra, Novartis (I), Synthekine (I), BeiGene (I)Consulting or Advisory Role: Seres TherapeuticsResearch Funding: Seres TherapeuticsPatents, Royalties, Other Intellectual Property: Dr van den Brink receives royalties from Wolters Kluwer, and he has intellectual property Licensing with Seres Therapeutics and Juno TherapeuticsTravel, Accommodations, Expenses: Rheos MedicinesOther Relationship: DKMSUncompensated Relationships: Seres therapeutics, Notch Therapeutics, Pluto Therapeutics Miguel-Angel PeralesStock and Other Ownership Interests: NexImmuneHonoraria: MorphoSysConsulting or Advisory Role: Incyte, Merck, Servier/Pfizer, NexImmune, Novartis, MolMed, Medigene, Takeda, Nektar, AbbVie, Cidara Therapeutics, Celgene, Kite/Gilead, Bristol Myers Squibb, Omeros, Vor BiopharmaResearch Funding: Incyte (Inst), Miltenyi Biotec (Inst), Novartis (Inst), Kite, a Gilead company (Inst), Nektar (Inst) Maria Lia PalombaStock and Other Ownership Interests: Seres Therapeutics (I)Honoraria: Flagship Biosciences (I), Evelo Therapeutics (I), Jazz Pharmaceuticals (I), Therakos (I), Amgen (I), Merck (I), Seres Therapeutics (I)Consulting or Advisory Role: Flagship Biosciences (I), Novartis (I), Evelo Therapeutics (I), Jazz Pharmaceuticals (I), Therakos (I), Amgen (I), Merck (I), Seres Therapeutics (I), Kite, a Gilead company, Novartis, BeiGene, SynthekineResearch Funding: Seres Therapeutics (I)Patents, Royalties, Other Intellectual Property: Intellectual Property Rights (I), Juno intellectual property rights (Inst)No other potential conflicts of interest were reported.
- Published
- 2022
- Full Text
- View/download PDF
16. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
- Author
-
Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, and Krishnan A
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bortezomib adverse effects, Consolidation Chemotherapy, Dexamethasone adverse effects, Disease Progression, Female, Humans, Lenalidomide adverse effects, Maintenance Chemotherapy, Male, Melphalan administration & dosage, Middle Aged, Multiple Myeloma mortality, Multiple Myeloma pathology, Myeloablative Agonists administration & dosage, Progression-Free Survival, Prospective Studies, Remission Induction, Reoperation, Time Factors, Transplantation, Autologous, United States, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bortezomib administration & dosage, Dexamethasone administration & dosage, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation mortality, Lenalidomide administration & dosage, Multiple Myeloma therapy
- Abstract
Purpose: Single-cycle melphalan 200 mg/m
2 and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (OS) for transplantation-eligible patients with multiple myeloma (MM). We designed a prospective, randomized, phase III study to test additional interventions to improve PFS by comparing AHCT, tandem AHCT (AHCT/AHCT), and AHCT and four subsequent cycles of len, bortezomib, and dexamethasone (RVD; AHCT + RVD), all followed by len until disease progression., Patients and Methods: Patients with symptomatic MM within 12 months from starting therapy and without progression who were age 70 years or younger were randomly assigned to AHCT/AHCT + len (n = 247), AHCT + RVD + len (n = 254), or AHCT + len (n = 257). The primary end point was 38-month PFS., Results: The study population had a median age of 56 years (range, 20 to 70 years); 24% of patients had high-risk MM, 73% had a triple-drug regimen as initial therapy, and 18% were in complete response at enrollment. The 38-month PFS rate was 58.5% (95% CI, 51.7% to 64.6%) for AHCT/AHCT + len, 57.8% (95% CI, 51.4% to 63.7%) for AHCT + RVD + len, and 53.9% (95% CI, 47.4% to 60%) for AHCT + len. For AHCT/AHCT + len, AHCT + RVD + len, and AHCT + len, the OS rates were 81.8% (95% CI, 76.2% to 86.2%), 85.4% (95% CI, 80.4% to 89.3%), and 83.7% (95% CI, 78.4% to 87.8%), respectively, and the complete response rates at 1 year were 50.5% (n = 192), 58.4% (n = 209), and 47.1% (n = 208), respectively. Toxicity profiles and development of second primary malignancies were similar across treatment arms., Conclusion: Second AHCT or RVD consolidation as post-AHCT interventions for the up-front treatment of transplantation-eligible patients with MM did not improve PFS or OS. Single AHCT and len should remain as the standard approach for this population.- Published
- 2019
- Full Text
- View/download PDF
17. Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation.
- Author
-
Peled JU, Devlin SM, Staffas A, Lumish M, Khanin R, Littmann ER, Ling L, Kosuri S, Maloy M, Slingerland JB, Ahr KF, Porosnicu Rodriguez KA, Shono Y, Slingerland AE, Docampo MD, Sung AD, Weber D, Alousi AM, Gyurkocza B, Ponce DM, Barker JN, Perales MA, Giralt SA, Taur Y, Pamer EG, Jenq RR, and van den Brink MRM
- Subjects
- Biomarkers, Tumor metabolism, Feces microbiology, Female, Graft vs Host Disease microbiology, Humans, Male, Middle Aged, Neoplasms metabolism, Retrospective Studies, Transplantation, Homologous, Gastrointestinal Microbiome physiology, Hematopoietic Stem Cell Transplantation adverse effects, Neoplasms microbiology, Neoplasms surgery
- Abstract
Purpose The major causes of mortality after allogeneic hematopoietic-cell transplantation (allo-HCT) are relapse, graft-versus-host disease (GVHD), and infection. We have reported previously that alterations in the intestinal flora are associated with GVHD, bacteremia, and reduced overall survival after allo-HCT. Because intestinal bacteria are potent modulators of systemic immune responses, including antitumor effects, we hypothesized that components of the intestinal flora could be associated with relapse after allo-HCT. Methods The intestinal microbiota of 541 patients admitted for allo-HCT was profiled by means of 16S ribosomal sequencing of prospectively collected stool samples. We examined the relationship between abundance of microbiota species or groups of related species and relapse/progression of disease during 2 years of follow-up time after allo-HCT by using cause-specific proportional hazards in a retrospective discovery-validation cohort study. Results Higher abundance of a bacterial group composed mostly of Eubacterium limosum in the validation set was associated with a decreased risk of relapse/progression of disease (hazard ratio [HR], 0.82 per 10-fold increase in abundance; 95% CI, 0.71 to 0.95; P = .009). When the patients were categorized according to presence or absence of this bacterial group, presence also was associated with less relapse/progression of disease (HR, 0.52; 95% CI, 0.31 to 0.87; P = .01). The 2-year cumulative incidences of relapse/progression among patients with and without this group of bacteria were 19.8% and 33.8%, respectively. These associations remained significant in multivariable models and were strongest among recipients of T-cell-replete allografts. Conclusion We found associations between the abundance of a group of bacteria in the intestinal flora and relapse/progression of disease after allo-HCT. These might serve as potential biomarkers or therapeutic targets to prevent relapse and improve survival after allo-HCT.
- Published
- 2017
- Full Text
- View/download PDF
18. Myeloma in Elderly Patients: When Less Is More and More Is More.
- Author
-
Rosko A, Giralt S, Mateos MV, and Dispenzieri A
- Subjects
- Age Factors, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Multiple Myeloma pathology, Quality of Life, Hematopoietic Stem Cell Transplantation adverse effects, Multiple Myeloma therapy, Transplantation, Autologous adverse effects
- Abstract
Multiple myeloma is a plasma cell malignancy that occurs among older adults and accounts for 15% of all hematologic malignancies in the United States. Thirty-five percent of patients are diagnosed at age 75 or older. Novel therapeutics and routine use of autologous stem cell transplantation (ASCT) have led to substantial improvements in patient survival, although improvements have been more impressive among patients younger than age 65. Finding the balance between under- and overtreating elderly patients is one of the biggest challenges specific to them as a subgroup of patients with MM. Decision making about which therapies and their dose intensity and duration should be influenced by a patient's functional status, personal preferences, disease characteristics, and ability to tolerate therapy. ASCT should be considered for all patients younger than age 80, assuming that they are not frail. The attainment of a stringent complete response and minimal residual disease negativity is associated with improved progression-free and overall survival. Again, consideration of quality of life for these patients is paramount. Although there is a growing list of tools to sort through these issues, a fully integrated approach has not yet been finely tuned, leaving additional work to be done for the treatment of elderly patients with MM.
- Published
- 2017
- Full Text
- View/download PDF
19. Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services.
- Author
-
Giralt SA, Horowitz M, Weisdorf D, and Cutler C
- Subjects
- Aged, Humans, Myelodysplastic Syndromes mortality, Prognosis, Transplantation, Homologous, United States, Hematopoietic Stem Cell Transplantation, Medicaid, Medicare, Myelodysplastic Syndromes therapy
- Abstract
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoietic stem-cell disorders that result in varying degrees of cytopenia and risk of transformation into acute leukemia. Allogeneic stem-cell transplantation (SCT) is the only known cure for this disease. The treatment is routinely used for younger patients, but only a minority of patients older than the age of 60 undergo this procedure. The overall MDS incidence is 3.3 per 100,000, but the incidence in patients older than age 70 is between 15 and 50 per 100,000. The median age at presentation is 76 years. Medicare-age patients 65 or older represent 80% of the total population receiving an MDS diagnosis. In the United States, one of the obstacles to SCT for older patients with MDS has been lack of third party reimbursement. On August 4, 2010, the Centers for Medicare and Medicaid Services released their Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndrome. This memo states: "Allogeneic HSCT for MDS is covered by Medicare only for beneficiaries with MDS participating in an approved clinical study that meets the criteria below…. " In this review, we will summarize what is known regarding the role of allogeneic SCT in older patients as well as other elements that should be included within clinical trials that can provide the evidence necessary to demonstrate that allogeneic SCT should be a covered benefit for Medicare beneficiaries.
- Published
- 2011
- Full Text
- View/download PDF
20. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.
- Author
-
Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, and de Lima MJ
- Subjects
- Adenosine Deaminase Inhibitors adverse effects, Adenosine Deaminase Inhibitors pharmacology, Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents pharmacology, Intention to Treat Analysis, Male, Methotrexate administration & dosage, Methotrexate adverse effects, Methotrexate pharmacology, Middle Aged, Pentostatin adverse effects, Pentostatin pharmacology, Survival Analysis, Tacrolimus administration & dosage, Tacrolimus adverse effects, Tacrolimus pharmacology, Adenosine Deaminase Inhibitors administration & dosage, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation, Immunosuppressive Agents administration & dosage, Pentostatin administration & dosage, Transplantation Conditioning methods
- Abstract
Purpose: Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after matched unrelated, related, or mismatched related donor hematopoietic stem-cell transplantation (HSCT). Improved GVHD prevention methods are needed. Pentostatin, an adenosine deaminase inhibitor, leads to lymphocyte depletion with low risk of myelosuppression. We hypothesized that addition of pentostatin to GVHD prophylaxis with tacrolimus and mini-methotrexate may improve outcomes, and we conducted a Bayesian adaptively randomized, controlled, dose-finding study, taking into account toxicity and efficacy., Patients and Methods: Success was defined as the patient being alive, engrafted, in remission, without GVHD 100 days post-HSCT and no grade ≥ 3 GVHD at any time. Patients were randomly assigned to pentostatin doses of 0, 0.5, 1.0, 1.5, and 2.0 mg/m(2) with drug administered on HSCT days 8, 15, 22, and 30. Eligible patients were recipients of mismatched related (n = 10) or unrelated (n = 137) donor HSCT., Results: Median age was 47 years. Thirty-seven, 10, 29, 61, and 10 patients were assigned to the control and four treatment groups, respectively, with comparable baseline characteristics. Pentostatin doses of 1.0 and 1.5 mg/m(2) had the highest success rates (69.0% and 70.5%) versus control (54.1%). The posterior probabilities that the success rates were greater with 1.5 mg/m(2) or 1.0 mg/m(2) versus control are 0.944 and 0.821, respectively. Hepatic aGVHD rates were 0%, 17.2%, and 11.1%, respectively, for 1.5 mg/m(2), 1.0 mg/m(2), and control groups. No grades 3 to 4 aGVHD occurred in 11 HLA-mismatched recipients in the 1.5 mg/m(2) group., Conclusion: Pentostatin increased the likelihood of success as defined here, and should be further investigated in larger randomized, confirmatory studies.
- Published
- 2011
- Full Text
- View/download PDF
21. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
- Author
-
Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, and San Miguel J
- Subjects
- Boronic Acids therapeutic use, Bortezomib, Glomerular Filtration Rate, Hematopoietic Stem Cell Transplantation, Humans, Incidence, Melphalan therapeutic use, Multiple Myeloma therapy, Prognosis, Pyrazines therapeutic use, Renal Insufficiency epidemiology, Renal Insufficiency etiology, Thalidomide therapeutic use, Transplantation, Autologous, Multiple Myeloma complications, Renal Insufficiency therapy
- Abstract
Renal impairment is a common complication of multiple myeloma (MM). The estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula is the recommended method for the assessment of renal function in patients with MM with stabilized serum creatinine. In acute renal injury, the RIFLE (risk, injury, failure, loss and end-stage kidney disease) and Acute Renal Injury Network criteria seem to be appropriate to define the severity of renal impairment. Novel criteria based on eGFR measurements are recommended for the definition of the reversibility of renal impairment. Rapid intervention to reverse renal dysfunction is critical for the management of these patients, especially for those with light chain cast nephropathy. Bortezomib with high-dose dexamethasone is considered as the treatment of choice for such patients. There is limited experience with thalidomide in patients with myeloma with renal impairment. Thus, thalidomide can be carefully administered, mainly in the context of well-designed clinical trials, to evaluate if it can improve the rapidity and probability of response that is produced by the combination with bortezomib and high-dose dexamethasone. Lenalidomide is effective in this setting and can reverse renal insufficiency in a significant subset of patients, when it is given at reduced doses, according to renal function. The role of plasma exchange in patients with suspected light chain cast nephropathy and renal impairment is controversial. High-dose melphalan (140 mg/m(2)) and autologous stem-cell transplantation should be limited to younger patients with chemosensitive disease.
- Published
- 2010
- Full Text
- View/download PDF
22. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.
- Author
-
Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, Kröger N, Moreau P, Gahrton G, Gasparetto C, Giralt S, and Bensinger W
- Subjects
- Disease-Free Survival, Humans, Transplantation Conditioning methods, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation methods, Multiple Myeloma surgery
- Abstract
Purpose: To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group., Patients and Methods: In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized., Results: Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation., Conclusion: New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials.
- Published
- 2010
- Full Text
- View/download PDF
23. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.
- Author
-
Chanan-Khan AA and Giralt S
- Subjects
- Disease-Free Survival, Humans, Treatment Outcome, Antineoplastic Agents therapeutic use, Multiple Myeloma drug therapy
- Abstract
The goal of treatment for multiple myeloma (MM) is to improve patients' long-term outcomes. One important factor that has been associated with prolonged progression-free and overall survival is the quality of response to treatment, particularly achievement of a complete response (CR). There is extensive evidence from clinical studies in the transplant setting in first-line MM demonstrating that CR or maximal response post-transplant is significantly associated with prolonged progression-free and overall survival, with some studies demonstrating a similar association with postinduction response. Supportive evidence is also available from studies in the nontransplant and relapsed settings. With the introduction of bortezomib, thalidomide, and lenalidomide, higher rates of CR are being achieved in both first-line and relapsed MM compared with previous chemotherapeutic approaches, thereby potentially improving long-term outcomes. While standard CR by established response criteria has been shown to have differential prognostic impact compared with lesser responses, increasingly sensitive analytic techniques are now being explored to define more stringent degrees of CR or elimination of minimal residual disease (MRD), including multiparameter flow cytometry and polymerase chain reaction. Demonstrating eradication of MRD by these techniques has already been shown to predict for improved outcomes. Here, we review the prognostic significance of achieving CR in MM and highlight the importance of CR as an increasingly realizable goal at all stages of treatment. We discuss clinical management issues and provide recommendations relevant to practicing oncologists, such as the routine use of sensitive techniques for assessment of disease status to inform evidence-based decisions on optimal patient management.
- Published
- 2010
- Full Text
- View/download PDF
24. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
- Author
-
McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, and Giralt S
- Subjects
- Adult, Age Factors, Aged, Female, Humans, Leukemia, Myeloid, Acute pathology, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Remission Induction, Survival Rate, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute therapy, Neoplasm Recurrence, Local therapy
- Abstract
PURPOSE Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) primarily afflict older individuals. Hematopoietic cell transplantation (HCT) is generally not offered because of concerns of excess morbidity and mortality. Reduced-intensity conditioning (RIC) regimens allow increased use of allogeneic HCT for older patients. To define prognostic factors impacting long-term outcomes of RIC regimens in patients older than age 40 years with AML in first complete remission or MDS and to determine the impact of age, we analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR). PATIENTS AND METHODS We reviewed data reported to the CIBMTR (1995 to 2005) on 1,080 patients undergoing RIC HCT. Outcomes analyzed included neutrophil recovery, incidence of acute or chronic graft-versus-host disease (GVHD), nonrelapse mortality (NRM), relapse, disease-free survival (DFS), and overall survival (OS). RESULTS Univariate analyses demonstrated no age group differences in NRM, grade 2 to 4 acute GVHD, chronic GVHD, or relapse. Patients age 40 to 54, 55 to 59, 60 to 64, and > or = 65 years had 2-year survival rates as follows: 44% (95% CI, 37% to 52%), 50% (95% CI, 41% to 59%), 34% (95% CI, 25% to 43%), and 36% (95% CI, 24% to 49%), respectively, for patients with AML (P = .06); and 42% (95% CI, 35% to 49%), 35% (95% CI, 27% to 43%), 45% (95% CI, 36% to 54%), and 38% (95% CI, 25% to 51%), respectively, for patients with MDS (P = .37). Multivariate analysis revealed no significant impact of age on NRM, relapse, DFS, or OS (all P > .3). Greater HLA disparity adversely affected 2-year NRM, DFS, and OS. Unfavorable cytogenetics adversely impacted relapse, DFS, and OS. Better pre-HCT performance status predicted improved 2-year OS. CONCLUSION With these similar outcomes observed in older patients, we conclude that older age alone should not be considered a contraindication to HCT.
- Published
- 2010
- Full Text
- View/download PDF
25. Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
- Author
-
Braiteh F, Hymes SR, Giralt SA, and Jones R
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Boronic Acids administration & dosage, Bortezomib, Dexamethasone administration & dosage, Humans, Male, Multiple Myeloma etiology, Neoplasm Recurrence, Local therapy, Psoriasis complications, Pyrazines administration & dosage, Remission Induction, Hematopoietic Stem Cell Transplantation, Multiple Myeloma therapy, Psoriasis therapy
- Published
- 2008
- Full Text
- View/download PDF
26. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.
- Author
-
Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Ringdén O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, and Anasetti C
- Subjects
- Adult, Female, Graft vs Host Disease prevention & control, Humans, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Male, Middle Aged, Remission Induction, Survival Analysis, Transplantation, Homologous, Treatment Outcome, Bone Marrow Transplantation, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Transplantation Conditioning methods
- Abstract
Purpose: To determine the role of myeloablative conditioning and unrelated donor (URD) bone marrow transplantation in the treatment of patients with advanced B-cell chronic lymphocytic leukemia (CLL)., Patients and Methods: A total of 38 CLL patients received a matched URD transplant using bone marrow procured by the National Marrow Donor Program. The median age was 45 years (range, 26 to 57 years), the median time from diagnosis was 51 months, and the median number of prior chemotherapy regimens was three. Fifty-five percent of patients were chemotherapy refractory and 89% had received fludarabine. Conditioning included total-body irradiation in 92% of patients. Graft-versus-host disease (GVHD) prophylaxis consisted of methotrexate with cyclosporine or tacrolimus for 82% of patients., Results: Twenty-one patients (58%) achieved complete response and six (17%) achieved partial response. Incidences of grades 2 to 4 acute GVHD were 45% at 100 days and incidences of chronic GVHD were 85% at 5 years. Eleven patients are alive and disease free at a median of 6 years (range, 3.0 to 9.0 years). Five-year overall survival, failure-free survival, disease progression rates, and treatment-related mortality (TRM) were 33%, 30%, 32%, and 38% respectively., Conclusion: These data demonstrate that lasting remissions can be achieved after URD transplantation in patients with advanced CLL. High TRM suggest that myeloablative conditioning and HLA-mismatched donors should be avoided in future protocols, and it is mandatory to investigate transplant strategies with a lower morbidity and mortality, including the use of nonmyeloablative regimens.
- Published
- 2005
- Full Text
- View/download PDF
27. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.
- Author
-
Escalón MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, and Khouri IF
- Subjects
- Adult, Graft vs Host Disease, Humans, Middle Aged, Salvage Therapy, Transplantation Conditioning, Transplantation, Autologous, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation, Lymphoma, Non-Hodgkin therapy
- Abstract
Purpose: Allogeneic transplantation for patients with lymphoma who experience a recurrence after an autologous transplantation has been considered a hazardous therapeutic choice. We investigated the safety and efficacy of nonmyeloablative stem-cell transplantation in these patients., Patients and Methods: Patients were required to have chemosensitive or stable disease. Twenty consecutive patients were treated in two sequential trials. Fifteen patients underwent a preparative regimen of fludarabine (30 mg/m(2) daily for 3 days), intravenous cyclophosphamide (750 mg/m(2) daily for 3 days), and rituximab. For the remaining five patients, the conditioning regimen consisted of cisplatin (25 mg/m(2) continuous infusion daily for 4 days), fludarabine (30 mg/m(2) daily for 2 days), and cytarabine (1,000 mg/m(2) daily for 2 days). Tacrolimus and methotrexate were used for graft-versus-host disease prophylaxis., Results: All patients experienced engraftment of donor cells. One patient (5%) experienced grade 2 acute graft-versus-host disease, and no patients experienced a higher grade. One patient experienced disease progression at 115 days post-transplantation and responded to donor lymphocyte infusion. The remaining patients remained disease-free. One patient died at 10.5 months from a fungal infection. With a median follow-up time of 25 months, the estimated 3-year current progression-free survival rate was 95%., Conclusion: These data suggest that nonmyeloablative allogeneic stem-cell transplantation is an effective option in lymphoma patients with chemosensitive or stable disease who experience disease recurrence following autologous transplantation.
- Published
- 2004
- Full Text
- View/download PDF
28. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma.
- Author
-
Wang XS, Giralt SA, Mendoza TR, Engstrom MC, Johnson BA, Peterson N, Broemeling LD, and Cleeland CS
- Subjects
- Activities of Daily Living, Acute Disease, Adolescent, Adult, Aged, Aged, 80 and over, Fatigue epidemiology, Fatigue physiopathology, Female, Humans, Male, Middle Aged, Prevalence, Serum Albumin analysis, Severity of Illness Index, Fatigue etiology, Leukemia complications, Leukemia therapy, Lymphoma, Non-Hodgkin complications, Lymphoma, Non-Hodgkin therapy
- Abstract
Purpose: To describe fatigue severity, fatigue interference, and associated factors in hematologic malignancies., Patients and Methods: Patients being treated for leukemia and non-Hodgkin's lymphoma (n = 228) completed the Brief Fatigue Inventory to rate fatigue severity and functional interference caused by fatigue. Data on patient demographics, Eastern Cooperative Oncology Group performance status, other physical symptoms, current treatments, and laboratory values were also collected. Descriptive statistics, bivariate correlation, and logistic regression were used for data analysis., Results: Fifty percent of the sample reported severe fatigue, which was defined as a "fatigue worst" rating of 7 or greater. More patients with acute leukemia (61%) reported severe fatigue compared with those with chronic leukemia (47%) and non-Hodgkin's lymphoma (46%). Increased fatigue severity significantly compromised patients' general activity, work, enjoyment of life, mood, walking, and relationships with others. Fatigue severity was strongly associated with performance status, use of opioids, blood transfusions, gastrointestinal symptoms, and sleep disturbance items, as well as with low serum hemoglobin and albumin levels. Regression analysis indicated that nausea was the significant clinical predictor of severe fatigue (odds ratio, 13), and low serum albumin was the significant laboratory value predictor (odds ratio, 3.8)., Conclusion: Disabling fatigue occurs with high frequency in hematologic malignancy, supporting a need to develop better methods of fatigue management. Better control of gastrointestinal and other symptoms may be of benefit. The mechanism and relationship between low albumin and severe fatigue needs to be investigated further, and longitudinal studies of the effects of treatment, host factors, and other symptoms are needed.
- Published
- 2002
- Full Text
- View/download PDF
29. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.
- Author
-
Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski WR, Barrett AJ, Porter DL, Giralt S, Leis J, Holmes HE, Johnson M, Horowitz M, and Collins RH Jr
- Subjects
- Adolescent, Adult, Blood Donors, Child, Child, Preschool, Disease-Free Survival, Female, Graft vs Host Disease, Granulocyte Colony-Stimulating Factor administration & dosage, Humans, Infant, Injections, Subcutaneous, Leukemia, Myeloid pathology, Male, Middle Aged, Prognosis, Prospective Studies, Recurrence, Salvage Therapy, Transplantation, Homologous, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow Transplantation, Granulocyte Colony-Stimulating Factor pharmacology, Leukemia, Myeloid therapy, Leukocytes
- Abstract
Purpose: Patients with advanced myeloid malignancies who experience relapse after allogeneic bone marrow transplantation (BMT) have a poor prognosis. Long-term survival after chemotherapy alone, second myeloablative transplant, or donor leukocyte infusions (DLIs) alone is unusual. DLIs may have minimal effectiveness in advanced disease because adequate cellular responses are not able to develop in the presence of bulky, fast-growing disease. A chemotherapy strategy was used to debulk disease before administration of granulocyte colony-stimulating factor (G-CSF)-primed DLIs., Patients and Methods: Sixty-five patients experiencing hematologic relapse of myeloid malignancy after HLA-matched sibling BMT were prospectively treated with cytarabine-based chemotherapy, then G-CSF-primed DLIs. No prophylactic immunosuppression was provided., Results: Twenty-seven of 57 assessable patients experienced a complete response. Graft-versus-host disease (GVHD) was observed in 56% of the patients. Treatment-related mortality was 23%. Overall survival at 2 years for the entire cohort was 19%. Patients with a complete response were more likely to survive, with 1- and 2-year survival rates of 51% and 41%, respectively, with a median follow-up of more than 2 years. The 1-year survival for nonresponders was 5%. A posttransplant remission lasting more than 6 months before relapse was associated with a higher likelihood of response. GVHD was not required for durable remission., Conclusion: Salvage treatment with chemotherapy before DLI can help some patients with advanced myeloid relapse and is not dependent on GVHD. Patients with short remissions after BMT are unlikely to benefit from this approach, and the approach is associated with significant treatment-related mortality. Modifications of this approach or entirely different approaches will be required for most patients with this difficult clinical problem.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.